

DAFTAR PUSTAKA

- Aditama, 2002, Paru Kita Masalah Kita, *Majalah Kesehatan Medika*, **11**, 743-745.
- Anonim, 2007, *Pharmaceutical care untuk Penyakit Asma*, Depkes RI, Jakarta.
- Anonim, 2017, Profil Kesehatan Provinsi DIY 2017, Depkes RI, Jakarta.
- Aslam, M., Tan, C.K. & Prayitno, A., 2003, *Farmasi Klinis*, Elex Media Komputindo, Jakarta.
- Barnes, P.J., 2010, Theophylline, *Phrmaceuticals.*, **3**, 725 - 747.
- Barnes, P.J., 2013, Theophylline, *American Journal of Respiratory and Critical Care Medicine.*, **188** (8), 901 – 906.
- Baxter, K., 2010, *Stockley's Drug Interactions : A Source Book of Interactions, Their Mechanism, Clinical Importance and Management*, Pharmaceutical Press, London.
- Calis, K. A., Sidawy, E. N., Young, L. R., 2007, *Principles of Clinical Pharmacology, Second Edition*, Academic Press, Maryland.
- Dipiro, J. T., Talbert R.L., Yee Gry C., Matzke G. R., Wells B. G., Posey L. M., 2011, *Pharmacotherapy : A Pathophysiologic Approach*, 8th, Mc Graw Hill, New York.
- Global Initiative for Asthma (GINA), 2018, *Global Strategy for sthma Management and Prevention*.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2018, *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease*.
- Huang Zhi L., Zhang Z., Qu W. M., 2014, Roles of Adenosine and Its Receptors in Sleep Wake Regulation, *Interntional Review of Neurobiology*, **119**, 349 – 371.
- Igarashi T, Iwakawa S, 2009, Effect of gender on theophylline clearance) in the asthmatic acute phase in Japanese pediatric patients. *Biol Pharm Bull*, **32**, 304-307.
- Ishizaki, T., Horai Y., Sasaki T., Chiba K., Ohnishi ., Sugnum T., Tsujimoto G., Echizen H., Okaniwa T., 1983, Biovilibility and Pharmacokinetics of theophylline Following Plain Uncoted and Sustain-Release Dosage Forms in relation to Smoking Habit, *European Journal of Clinical Pharmacology*, **24**, 361-369.
- Ismail, L., Sahrudin, Ibrahim K., 2017, Analisis Faktor Resiko Kejadian Penyakit Paru Obstruksi Kronik (PPOK) di Wilayah Kerja Puskesmas Lepo – Lepo Kota Kendari Tahun 2017, *Jimkesmas*, **3** (6), 1-10.
- Kando JC, Yonkers KA, Cole JO, 1995, Gender as a risk factor for adverse events to medications, *Drugs*, **50**, 1–6.
- Kelly H.W., dan Sorkness C., 2011. Asthma, Dalam Dipiro J., Talbert R., Yee G., Matzke G., Wells B., Posey M., *Pharmacotherapy: A Phatophysiologic Approach*, 8th Edition., McGrWHill, New York.
- Lacy, Charles F., Amstrong Lora L., Goldman M. P., Lance L. L., 2011, *Drug Information Handbook*, 20th edition, Lexi-comp Inc., United States.
- Lorensia, A., Amalia R. A., 2015, Studi Farmakovigilans Pengobatan Asma pada Pasien Rawat Inap di Suatu Rumah Sakit di Bojonegoro, *Jurnal Ilmiah*

- Manuntung*, **1** (1), 8-18.
- Lorensia, A., Ikawati, Z., Andayani, T. M., Suryadinata R. V., Hantoro K., firanita L. D., 2018, Efektivitas dan Resiko Toksisitas Aminofilin Intravena pada Pengobatan Awal Serangan Asma, *Jurnal Farmasi Klinik Indonesia*, **7** (2), 78 – 88.
- Lutfiyati, H., Ikawati, Z. & Wiedyaningsih, C., 2015, Efek Samping Penggunaan Terapi Oral pada Pasien Asma, *Jurnal Farmasi Sains dan Praktis*, **I** (1), 21 – 28.
- Lutfiyati, H., Wiedyaningsih, C., 2015, *Efek Samping Penggunaan Terapi Oral Pada Pasien Asma*, Jurnal Farmasi Sains dan Praktis, Vol. I, No. 1.
- Muhammad, E. P., Murni A. W., Sulastri Delmi., Miro S., 2016, Hubungan Derajat Keasaman Cairan Lambung dengan Derajat Dispepsia pada Pasien Dispepsia Fungsional, *Jurnal Kesehatan Andalas*, **5** (2), 371 – 375.
- National Asthma Education and Prevention Program (NAEPP), 2007, *Guidelines for the Diagnosis and Management of Asthma*.
- Nuari, Anwar, Soleha T. U., Maulana M., 2018, Penatalaksanaan Asma Bronkial Eksaserbasi pada Pasien Perempuan Usia 46 Tahun dengan Pendekatan Kedokteran Keluarga di Kecamatan Gedong Tataan, *Majority*, **7** (3), 143 – 151.
- Ohta, K., Fukuchi, Y., Grouse, L., Mizutani, R., Rabe, K., Rennard, S., Zhong, N., 2004, *A Prospective Clinical Study of Theophylline Safety in 3810 elderly with Asthma or COPD*, Respiratory Medicine, Tokyo, 98, 1016 – 1024.
- Oktavia, W., 2012, *Faktor-faktor yang Mempengaruhi Kualitas Hidup Penderita Penyakit Paru Obstruksi Kronis (PPOK) di RSUD Arifin Achmad*, Program Studi Ilmu Keperawatan Universitas Riau, Pekanbaru.
- Oemiati, Ratih, 2013, Kajian Epidemiologis Penyakit Paru Obstruksi Kronik (PPOK), *Media Litbangkes*, **23** (2), 82 – 88.
- Palinoan, H. S., Agustina R., Rijai L., 2015, Studi Karakteristik Pasien Penyakit Paru Obstruksi Kronik (PPOK) di RSUD A. W Sjahranie Samarinda Periode Januari – Desember 2014, Universitas Mulawarman, Samarinda.
- Papi, Alberto, Brightling C., Pedersen S.E., dan Reddel H.K., 2018, Asthma, *The Lancet*, **391**, 1-18.
- Perhimpunan Dokter Paru Indonesia (PDPI), 2003, *Asma : Pedoman Diagnosis dan penatalaksanaan di Indonesia*.
- Perhimpunan Dokter Paru Indonesia (PDPI), 2003, *Penyakit Paru Obstruktif Kronik (PPOK) : Pedoman Diagnosis dan penatalaksanaan di Indonesia*.
- Raherison, C. & Girodet, P.O., 2009, *Epidemiology of COPD*, European Respiratory Review, 18 (114), 213–221.
- Rai, I.B., Ngurah., Sajinadiyasa., 2008. *Hubungan Merokok dan Lama Rawat Inap Pasien Asma Eksaserbasi Akut di RSUP Sanglah Denpasar*, Universitas Udayana, Denpasar.
- Schatz, S.N. & Weber, R.J., 2015, Adverse Drug Reactions, *PSAP*, 5 – 26.
- Sidabutar, P & Rasmaliah H., *Karakteristik Penderita Penyakit Paru Obstruksi Kronik (PPOK) yang Di Rawat Inap di RSUP dan Malik Tahun 2012*, Universitas Sumatra Utara, Medan.
- Stojkovicj, J., Zafirova-Ivanovska, B., Kaeva, B., Anastasova, S., Angelovska, I.,

- Jovanovski, S., Stojkovikj, D., 2016, The Prevalence of Diabetes Mellitus in COPD Patients with Severe and Very Severe Stage of the Disease, *Open Access Macedonian Journal of Medical Sciences*, 4 (2), 253–258.
- Tatro, David S., 2012, *Drug Interaction Facts 2012: The Authority on Drug Interactions*, St. Louis, Missouri: Wolters Kluwer Health/Facts and Comparisons.
- Trembath, P.W., and Boobis, S. W., 1980, Pharmacokinetics of A Sustained-Release Theophylline Formulation, *Br. J. Clin. Pharmacol*, **9**, 365 – 369.
- Tyagi, N., Gulati, K., Vijayan, V.K. & Ray, A., 2007, A Study to Monitor Adverse Drug Reactions in Patients of Chronic Obstructive Pulmonary Disease : Focus on Theophylline, *The Indian Journal of Chest Diseases & Allied Sciences*, **50**, 199 – 202.
- Vollmer, W.M., 2003, Epidemiology of COPD : Overview and The US Perspective, *European Respiratory Journals*, **43**, 2s – 3s.
- Walker, R & Whittlesea, C., 2007, *Clinical Pharmacy and Therapeutics*, 4th Edition, Churchill Livingstone Elsevier, London.
- Wells, B. G., DiPiro, J. T., Schwinghammer, T. L. & DiPiro, C. V., 2015, *Pharmacotherapy Handbook*, 9th Edition, McGraw-Hill Education, US.
- Wisman, B. A., Mardhiyah R., Tenda Eric D., 2015, Pendekatan Diagnostik dan Tatalaksana Penyakit Paru Obstruktif Kronik GOLD D: Sebuah Laporan Kasus, *Indonesian Journal of CHEST*, **3** (4), 180 – 190.
- Yanti, B., dan Rasmin M., 2016, Peran Xantin pada Penyakit Obstruksi Paru, *Jurnal Respirologi Indonesia*, **36** (4), 267 - 273.
- Yip, L., dan Kwok, Y. N., 2004, Role of Adenosine A_{2A} Receptor in the Regulation of gastric Somatostatin Release, *The Journal of Pharmacology and Experimental Therapeutics*, **309** (2), 804 – 815.
- Young, R.P., Hopkins, R.J., Christmas, T., Black, P.N., Metcalf, P., Gamble, G.D., 2009, COPD prevalence is increased in lung cancer, independent of age, sex and smoking history, *European Respiratory Journal*, 34 (2), 380–386.